100 Key Veterinary Medicines With Estimated Sales, 2018 - 2022

Methodology

• Leading companies in the animal health market were identified
• Annual reports, investor presentations, press releases, and product brochures of these companies were studied in detail. Information was also gleaned from paid databases such as Pitchbook.
• Blockbuster products and other leading revenue-generating products were identified along with segment revenues reported by the companies
• The data was plugged into our estimation models consisting of a hybrid approach (top down and bottom up) and variable analysis to derive product or product line specific revenues for consecutive years
• Some of the factors considered while estimating sales of veterinary medicines include:
• Product approvals
• Regulatory landscape
• Product usage and penetration
• ASP
• Patent analysis
• Competition from generics

Scope

• Brand name
• INN (Active Ingredient)
• Molecular Weight
• Company
• First Approval/ Launch Year
• Indication
• Type
• Category
• Dosage Form
• Target Species
• Estimated Global Sales (USD million, 2018 to 2030)
• ASP (in USD)
• Commercialized/ Available in
• Patent/ Generics Information
• Notes

The above information would be provided for the following companies

• Boehringer Ingelheim International GmbH
• Dechra Pharmaceuticals PLC
• Elanco
• Virbac
• Zoetis
• Merck & Co., Inc.
• Phibro Animal Health
• Neogen Corporation